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Abstract 4 
Cancer spread (metastasis) is responsible for 90% of cancer-related fatalities.  Informing patient treatment to prevent metastasis, or kill all cancer cells in a 5 
patient’s body before it becomes metastatic is extremely powerful.  However, aggressive treatment for all non-metastatic patients is detrimental, both for 6 
quality of life concerns, and the risk of kidney or liver-related toxicity. Knowing when and where a patient has metastatic risk could revolutionize patient 7 
treatment and care. In this review, we attempt to summarize the key work of engineers and quantitative biologists in developing strategies and model 8 
systems to predict metastasis, with a particular focus on cell interactions with the extracellular matrix (ECM), as a tool to predict metastatic risk and tropism. 9 
Introduction 10 
Metastasis, the spread of cancer cells from an initial tumor site to other areas of the tissue, or to other tissues entirely, is the 11 
cause of 90% of cancer-related deaths. Cancer does not metastasize randomly, rather each type of cancer exhibits a tissue-12 
specific pattern of spread (called tropism) [3]. Some types, like colon [6] and ovarian cancer [7], are dictated by circulation 13 
patterns and anatomical proximity. But other types of cancer metastasize to distant organs independently of circulation. 14 
Prostate cancer metastasizes nearly exclusively to the bone [8], pancreatic cancer to the lung and liver, and other types, like 15 
breast and non-small cell lung cancer, spread to many tissues ([3], Figure 1).  16 
 17 
By and far, evidence for what might control metastasis to certain tissues, but not others, has focused on the genetic 18 
determinants of the seed (the cancer cell) that dictate tissue selectivity (tropism) [9-13]. Here, we summarize engineered model 19 
systems to study the role of the soil (the extracellular matrix, ECM) in mediating metastasis.  We discuss cell-ECM interactions 20 
and physical forces in guiding metastasis, with a focus on breast cancer. We discuss the community’s ability to predict when and 21 
where cancer cells will metastasize, and speculate what these predictions mean for patient prognosis, surveillance, and drug 22 
treatment.   23 
Predicting Invasion 24 
Preceding eventual metastatic colonization at a secondary tissue, primary tumor cells must first invade through the basement 25 
membrane into the surrounding interstitial tissue. Biopsies are the gold standard for determining the local invasiveness of a 26 
patient’s tumor upon diagnosis.  There are many biomarkers, such as proteins, miRNAs, and copy number alterations that can 27 
  
2 
identify a patient’s tumor as invasive [14-17]. However, biopsies only provide one snapshot of a tumor, with limited ability to 1 
predict any stochastic changes in phenotype or mutations that may occur, thus limiting the future efficacy of a patient’s drug 2 
treatment regimen. Recently, biologists and engineers have sought to understand how the ECM impacts the invasiveness of 3 
cancer, and if the ECM itself could be used as a predictive biomarker. 4 
 5 
Matrix and/or cell stiffness is one such potential predictive marker. Recently a study found that mice with more mechanically 6 
compliant primary tumors had more aggressive relapsed tumors at the time of euthanasia [18]. Shear stress due to fluid flow 7 
also induces an epithelial to mesenchymal transition (EMT) in ovarian cancer, suggesting that more porous tumors are more 8 
metastatic [19].  On in vitro 2D surfaces, Leight et al. found that TGF-1 induced invasion occurs only on rigid surfaces, thereby 9 
linking chemical and physical factors on the initiation of EMT [20]. A large study spearheaded by the National Cancer Institute 10 
(NCI) recently showed that physical differences (such as cell compliance, traction forces) are enough to distinguish between a 11 
malignant (MDA-MB-231) and normal (MCF-10A) cell line [21]. This study required massive efforts across many laboratories, so 12 
more sophisticated tools, perhaps those that rely on electrical impedance [22] instead of individual cell analysis, are required for 13 
high-throughput application.  14 
 15 
In addition to stiffness, many ECM proteins have documented roles in augmenting or abrogating metastasis (for review, see 16 
[23]).  In fact, Weinberg’s Hallmarks of Cancer was recently updated to include the role of the ECM in each step of metastasis 17 
[24]. The potential for metastasis and the particular distant tissue site may be associated with an identifying “ECM signature” 18 
[25]. For example, using ECM-binding as a predictive marker showed that cancer cell binding to combinations of ECM proteins 19 
was sufficient to separate metastatic from non-metastatic cell lines [26]. While these are seminal studies, a consistent predictive 20 
biomarker of disease prognosis, such as the structure of the ECM, or perhaps an individual or set of proteins within the ECM, has 21 
yet to be developed.  This is imperative to translate understanding of the physical relationship between a cell and its ECM to 22 
clinical treatment. 23 
Where will cancer metastasize? 24 
Given what we know about the heterogeneous nature of tropism, how do we predict where a cell will metastasize?  Ideally 25 
clinicians would be able to predict metastatic location with biomarkers in a tumor biopsy or in a blood draw, or with quick in 26 
vitro assays. An ideal in vitro platform would have controlled, decoupled properties, be highly reproducible, and be easily 27 
transferrable to different laboratories and clinics. In in vitro models, high invasion, motility, and proliferation are generally 28 
correlated with metastatic potential. One example recently shown by Sheetz and colleagues used simple control of mechanics to 29 
report that MDA-MB-231 variant cells proliferate in vitro on materials mechanically similar to the tissue to which they 30 
  
3 
metastasize to in vivo, (Figure 2, [2]). This work was reproduced in a comparative study between ovarian and breast cancer cells 1 
(Figure 2, [4]). These examples suggest that physical features may filter for populations of breast cancer cells that exhibit 2 
enhanced proliferative ability at specific secondary tissue sites, and that biomaterial platforms with controlled mechanics could 3 
be used to identify this proliferative capacity in vitro.  4 
 5 
Because the tissues recipient of breast cancer metastasis have 6 
striking differences in microenvironment composition, our lab 7 
and others have hypothesized that cell-matrix interactions may 8 
mediate tropism. We recently showed that integrin-mediated 9 
adhesion and motility phenotypes of breast cancer cells, 10 
compiled into a phenotypic fingerprint using a systems biology-11 
like approach, can predict bone, brain, or lung metastasis in 12 
breast cancer (Figure 2, [1]). In contrast to tools that rely on 13 
genetics or fixed tumor tissue (Oncotype DX, MammaPrint, 14 
MetaSite Breast, and Prosigna), these engineering approaches 15 
use live cell interactions with the microenvironment and may 16 
reveal prognostic results missed by traditional approaches.  17 
Tissue-Specific Drivers of Metastasis 18 
Within breast cancer, the pathological subtype of the disease is correlated with different rates of metastasis to different tissues 19 
(Figure 1c, [5]).  Bone metastases are by far the most common, occurring in 75% of all metastatic breast cancer patients. Brain 20 
metastases, on the other hand, are rare, occurring in roughly 15% of all patients, with ER- negative and HER2+ subtypes most 21 
commonly presenting.  Metastasis to the lungs occurs in approximately 25% of metastatic patients, with the highest 22 
presentations in HER2+, ER-/PR- breast cancer.  23 
 24 
Pioneering genetic research has identified a subset of genetic markers associated with tissue-specific metastasis. These include 25 
COX2, ST6GALNAC5, EGFR, HBEGF [12] L1CAM and SERPINS [27], and GABA for brain metastasis [28].  Bone tropic populations 26 
overexpress genes that facilitate metastasis: CXCR4 promotes homing and extravasation, MMP1 facilitates invasion, CTGF and 27 
FGF5 aid angiogenesis, and IL11 and OPN are involved with osteolysis and remodeling the bone matrix [10].   Similar studies using 28 
lung-tropic human cells have identified up to 54 potential genes in mice, most prominently IL13Rα2, SPARC, ID1, and VCAM1, to 29 
  
4 
be involved in breast-to-lung metastasis [13]. These genetic markers have thus far provided the only possible predictive 1 
biomarkers in the primary tumor, and could serve as future therapeutic targets in the clinic. 2 
 3 
To augment these genetic efforts, engineers are creating model systems, from simple-to-complex, to represent these tissue sites.  4 
These representations typically focus on healthy cells commonly found in these tissues, ECM protein composition, ECM stiffness, 5 
and tissue dimensionality. Hydrogels are popular tissue mimics because they recapitulate 3D tissue structure and physiological 6 
water content (Figure 3b) [29]. Natural hydrogels, such as collagen-based systems, elicit biochemical cues well, but over-7 
sequester media proteins and cannot simultaneously recapitulate tissue stiffness and biochemical properties. While synthetic 8 
polymers can be independently tuned mechanically and chemically, they can be over-simplified, and more fundamental research 9 
on tissue properties is needed to make these models more tissue-specific. To combine the advantages of both, Beck et al. 10 
combined tunable, synthetic PEG gels with the common cancer model system Matrigel to investigate cell invasion in response to 11 
ECM stiffness [30].  Interestingly, they found very similar responses by both cancerous and normal cells, as both had reduced 12 
proliferation/morphogenesis in stiff environments. An analogous study used interpenetrating networks of Matrigel and alginate 13 
(both natural materials with very different properties), and somewhat in contradiction to the previous study, could force a 14 
malignant transformation in healthy breast cells via ECM stiffening [31]. Here, we briefly review approaches used to make these 15 
platforms more tissue-specific, and research that can be used to improve future tissue design parameters, with the hopes of 16 
uncovering a consensus of how these matrix features drive metastasis. 17 
 18 
The most comprehensive study on tissue proteomics is available through the Proteinatlas (proteinatlas.org), which has 19 
annotated ~17,000 protein-coding genes across 32 tissues using both antibodies and RNAseq [32]. The brain ECM consists mainly 20 
of hyaluronan (HA) bound by lecticans and tenascin-R with some laminin, fibronectin, collagen IV, and heparin sulfate 21 
proteoglycans [33, 34].  Cancer cell binding to the brain ECM through integrins αvβ3 and αvβ6 [35] is also a possible biomarker of 22 
brain metastasis risk. The composition of the lung ECM is primarily elastin, collagen I, laminins, and glycosaminoglycans [36]. 23 
Upregulation and production of tenascin C, a transient glycoprotein, has been found along with lung metastases and is a sign of 24 
poor prognosis [13, 37]. Bone is a composite tissue, dominated by collagen I on the hard trabecular/cortical bone, and fibrillar 25 




Researchers are using a variety of techniques to quantify the rigidity of these tissue sites (Figure 3).  Reports on the mechanical 1 
properties (stiffness) of brain tissue are primarily limited to elastography [38, 39], a technique not commonly performed on in 2 
vitro model systems.  Obtaining human brain tissue for ex vivo mechanical testing is challenging, therefore indentation studies 3 
are limited to animal models, and report Young’s moduli ranging from 1-2 kPa in Young’s modulus [40]. The stiffness of the lung 4 
parenchyma has been measured using a variety of techniques in multiple animal models with a Young’s modulus ranging from 2 5 
to 8 kPa [41-43]. Trabecular and cortical bone is markedly stiff (~10GPa).  Our lab recently reported the first physiological values 6 
for intact bone marrow tissue stiffness (0.3-24.7 kPa), and we anticipate that improving the mechanical relevance of in vitro 7 
systems will elucidate mechanisms involved in breast-to-bone cancer progression [44].  8 
 9 
A key defining characteristic of the skeleton in addition to its high stiffness is its cyclic mechanical nature - the primary regulator 10 
of bone cell function and remodeling [45], alongside increased pressure and fluid shear forces on cells within. When cancer cells 11 
arrive in the skeleton, they too are exposed to these cyclic signals, such as compression, hydrostatic pressure, and fluid shear 12 
stress. Tumor formation in the bone is inhibited in both breast and ovarian cancer during mechanical load [46, 47]. However, the 13 
magnitude of shear stresses and strains in the bone ECM are sufficient for driving malignancy in primary cancer cells in vitro [48], 14 
so understanding these relationships may help predict breast-to-bone metastasis. 15 
 16 
Figure 2: Predicting metastasis and  
potential impact on therapy.  a) Cells that 
metastasized to bone and lung in vivo 
shared similar in vitro motility 
characteristics, adapted from Kostic et al. 
[2].  b) Mechanosensitivity can be used to 
distinguish between breast cancer 
metastatic cells (MDA-MB-231) and 
ovarian cancer metastatic cells (SKOV-3), 
from McGrail et al. [4]. c) Barney et al. 
developed an in vitro screen that used 
integrin-binding to predict in vivo 
metastasis to the bone, brain, and lung, 
as well as identify integrin subunits as 
tissue-specific risk factors [1] ADD 
REFERENCE. d-f) One can envision that 
these types of predictive screens could 
impact therapy for patients with different 
risk factors for developing metastatic 
disease.  Patients with low risk of 
metastasis could be shielded from harsh 
treatment modalities (d), whereas 
patients at risk for metastasis (e, f) could 
be treated aggressively to help prevent 
metastasis or relapse.  
  
6 
Engineers have used these analyses as inspiration to create in vitro model systems of brain, bone, and lung tissue, to quantify 1 
interactions cancer cells with tissue-specific ECMs. In vitro models of brain include those based on HA [49], HA crosslinked with 2 
PEG [50], silk [51, 52], brain tissue slices, microfluidic devices, and some have begun using 3-D bioprinting [53, 54]. In vitro, cells 3 
that have been selected for lung metastasis have been found to grow optimally on intermediately stiff 3D hydrogel environments 4 
[2].  Decellularized tissues have been used to mimic bone ECM [55], as well as synthetic and silk-based scaffolds with either 5 
inverted colloidal geometry or electrospinning, functionalized with proteins found in bone [56, 57]. When implanted, they can 6 
capture circulating tumor cells [58].  7 
 8 
Microfluidic systems can also capture features of cancer cell extravasation into bone-like matrices in the presence of local 9 
mesenchymal stem cells (MSCs) and endothelial cells [59]. One such lab developed a 3D metastasis model, called rMet, which is 10 
composed of ECM proteins characterizing of primary and secondary (bone) tissues sites of cancer metastasis [60].  Cancer cells 11 
that were highly invasive into their bone ECM were also highly metastatic to the bone in mice, demonstrating that an in vitro 12 
system can be predictive of in vivo behavior.   13 
 14 
Combined with experimental results, predictive algorithms can be derived and incorporated into mechanics simulations. For 15 
example, Wang et al. incorporated osteocyte viability algorithms into their models simulating disuse and recovery to predict 16 
when bone tissue would undergo resorption or formation [61]. These types of systems could be used for metastasis studies, to 17 
predict how cancer cells will behave under a particular mechanical environment (e.g. will they be dormant, will they migrate 18 
elsewhere, fracture risk after a potential drug, etc). 19 
 20 
The next step for model systems is to incorporate these matrices with vasculature [62, 63] for a more complete assessment of 21 
the metastatic cascade, and to translate these phenomenological behaviors into biomarkers useful for clinicians and patients at 22 
risk of metastasis, such as those identified in vivo [64].   23 
Dormancy 24 
Breakthrough research has revealed the existence of dormant tumor cells: metastasized cells quiescent at the metastatic site 25 
that may not proliferate, or “awaken” for several years, even decades, and are extremely difficult to detect and treat. Local 26 
stromal cells in the metastatic niche likely play a dominant role in paracrine activation of dormant cells, such as glial cel ls in the 27 
brain [65], and hepatocytes and non-parenchymal cells in the liver [66]. Vasculature plays a dual role, in some cases maintaining 28 
quiescence [67], and releasing the factors critical for re-activation in others [68]. Both Ghajar [69] and Aguirre-Guiso et al. [70] 29 




In vitro, cell adhesion to specific stromal-derived matrices [71], or substrates of particular stiffnesses [72] can permit dormancy. 2 
Specific combinations of bone marrow or hepatic stromal cells can induce breast cancer cell dormancy via cytokine secretion [66, 3 
73]. For example, the Griffith lab used an engineered liver tissue to study stromal cell and ECM re-activation of dormant breast 4 
cancer cells in the liver [66].  They found that roughly half of infiltrated breast cancer cells were dormant, and not surprisingly, 5 
the more aggressive MDA-MB-231 cells were more sensitive to re-activation by non-parenchymal cells than the luminal MCF7s.   6 
 7 
In combination with these systems, traditional culture platforms allow for selection of quiescent subpopulations, via isolating 8 
dormant cells after therapeutic administration [74] or from biomaterial systems that induce dormancy. By coupling these 9 
subpopulations with engineered microenvironments, it will be possible to accurately determine how therapy may be directed to 10 
induce dormancy and eradicate quiescent cells, preventing metastatic outgrowth altogether [69].  11 
Predicting drug response for metastatic patients 12 
Ideally, once metastasis risk is assessed, developing patient-specific drug regimes will follow.  Anti-metastasis drugs include those targeted 13 
at vascularization, growth in certain microenvironments, cell-ECM binding, receptor kinases, and cancer stem cells (Figure 2d-f) [75].  In 14 
vitro model systems are being developed to test for drug response in more physiologically relevant microenvironments that could be 15 
tailored to specific tissue sites. A recent example is a 4D lung model, in which circulating tumor cells were as resistant to cisplatin in the 16 
model as they were in vivo, results not captured on 2D surfaces [76].  Similarly, combining ovarian cancer cells with fibroblasts in a 17 
representative ECM system recapitulated in vivo drug response [77].  These types of organotypic representations of tissue for drug 18 
screening are likely to become increasingly popular with the advent of patient-derived cultures [78]. These systems can be used with a 19 
Figure 3: In vitro models of the metastatic 
niche.  a) Common sites of breast cancer 
metastasis and their published stiffnesses 
(Young’s modulus).  These sites consist of 
tissue-specific cell types that are part of the 
metastatic niche.  b) These tissues can be 
represented by natural protein fiber gels or 
synthetic polymer materials.  Polymer matrices 
can be modified to allow for tissue-specific cell-
ECM interactions (via integrin binding) by 
including oligopeptides responsible for the 
integrin-binding domains of full-length ECM 
proteins typically found in these tissues. 
  
8 
more reductionist approach as well, e.g., ECM stiffness has been reported to be a powerful mediator of drug response for paclitaxel [79], 1 
ibuprofen [80], and sorafenib [81]. Ideally, the findings demonstrated here can be related to quantifiable, predictive biomarkers, informing 2 
drug treatment and monitoring.   3 
Conclusions 4 
Our discussion here was limited to experimental model systems to understand, predict, and treat metastatic spread.  There is a keen need 5 
for computational methods to better inform and guide these experiments, such as how cells can resist chemotherapy treatment on the 6 
basis of likely heterogeneous drug distribution [82]. To our knowledge, no in silico approaches have been employed at point of care to 7 
predict metastatic spread. In addition, we suggest a need for computational experts to apply population-level survival models alongside 8 
kinetics to create a global map of cell trafficking from the primary tumor to eventual metastasis and growth in a secondary tissue site.  This 9 
could include a probabilistic model of mutations inducing invasion, trafficking and dispersion throughout the body via circulation, and 10 
eventual rates of dormancy or rapid growth at a distant site. Experimental model systems are growing, and an increasing number of 11 
engineers are applying their expertise to cancer metastasis. Model system improvements include increasing their throughput, including 12 
patient-derived cells, and translating their predictive findings into clinically useful biomarkers. 13 
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